Wat is de prijs voor RepliCel Life Sciences Inc. (RP)

Het prijs van RepliCel Life Sciences Inc. (RP) is $0.01100905

Wat is de marktkapitalisatie voor RepliCel Life Sciences Inc. (RP)

Marktkapitalisatie voorRepliCel Life Sciences Inc. (RP) is $810.02K

RepliCel Life Sciences Inc. (RP) Prijs en Marktkapitalisatie

Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.

Prijs voor RP	Aandeel B	Marktkapitalisatie van B	uitslagen
$74,115.58 $810.02K	NVDA	$5.453T	+673,223,809.47%
$60,970.12 $810.02K	AAPL	$4.486T	+553,817,905.77%
$56,528.14 $810.02K	GOOG	$4.159T	+513,469,519.01%
$50,167.86 $810.02K	MSFT	$3.691T	+455,696,319.38%
$38,639.45 $810.02K	AMZN	$2.843T	+350,978,769.42%

Prijs voor RP

Aandeel B

Marktkapitalisatie van B

uitslagen

$74,115.58 $810.02K